Nifty slips 0.46% as oil, Middle East risks pressure Indian equities

Indian equities closed lower in a risk-sensitive session as renewed uncertainty over the reopening of the Strait of Hormuz pushed crude higher and revived concerns about inflation, bond yields and corporate input costs. The decline was broad enough to keep market breadth weak, although pharma, technology and selected oil-and-gas stocks provided some support.

The immediate market implication is that global energy and rates remain more influential than domestic liquidity. Foreign investors were net buyers in the latest available cash-market data, but that support did not fully offset pressure on banks, consumer-facing counters, cement and travel-linked stocks.

The main external trigger was the apparent impasse in US-Iran discussions over the Strait of Hormuz. Brent crude was reported near $87.70 a barrel, while gold traded near $4,400 an ounce. Higher oil raises the risk of imported inflation for India and can pressure margins in transport, consumer goods, chemicals and other energy-intensive businesses.

The sector pattern reflected that backdrop. Pharma benefited from stock-specific earnings and rating support, particularly Gland Pharma, whose first-quarter earnings were reported to have exceeded analysts’ expectations. Technology stocks showed relative resilience, while travel and leisure faced renewed concern over fuel costs. Cement and materials were vulnerable to the combination of higher input costs and a cautious growth outlook.

Banks and financial services lagged despite continued foreign buying in the latest available flow data. The pressure appeared to be part of the broader de-risking response to higher oil prices, rising bond yields and uncertainty ahead of US inflation data, rather than a single policy announcement.

No RBI, SEBI or Finance Ministry action was reported for August 11. No release of Indian CPI, IIP, GST, trade or PMI data was identified in the available material.

The rupee was reported at ₹95.38 per US dollar, compared with ₹95.30 at the previous close in one market update. The benchmark 6.94% 2036 government bond yield was reported at 6.7907% at 11:45 a.m., against 6.7643% at Monday’s close; a final end-of-day yield was not available.

The bond-market move matters because higher crude can raise inflation expectations and reduce room for monetary easing. Investors were also awaiting US inflation data, which could affect global rate expectations and foreign flows into emerging markets, including India.

Wall Street ended modestly lower on Monday, while Asian equities traded with a cautious bias. US 10-year Treasury yields were reported around 4.70% to 4.73%, and the dollar index was near 99.8. The combination of higher oil and higher yields is a difficult backdrop for emerging-market equities because it raises both inflation and financing concerns.

The latest available institutional-flow data, for August 10, showed foreign investors as net buyers of ₹1,974.76 crore and domestic institutions as net sellers of ₹1,290.29 crore. August 11 end-of-day FII and DII figures were not available in the material.

For Indian markets, the next cross-asset signals are likely to come from the direction of crude, the rupee and US inflation expectations. A sustained oil shock would be relevant not only for the index but also for corporate margins, the government bond market and the external balance.

Oil India shares rose sharply after strong first-quarter results prompted Emkay Global to upgrade the stock to Buy, citing attractive valuations, higher crude production and improving gas-evacuation prospects. Elara Capital retained its Buy rating, while Nomura and Motilal Oswal maintained neutral views.

Info Edge reported a 43% year-on-year rise in consolidated first-quarter net profit to ₹490 crore. Recruitment billings grew 17.5% and operating profit rose 25%, helping the stock outperform. The available material did not provide the numerical consensus estimate against which the result was measured.

Gland Pharma’s earnings were described as better than analysts’ expectations, and Jefferies upgraded the stock from Hold to Buy. No numerical estimate or actual earnings figure was provided for the comparison.

Among other reported results, TCPL Packaging’s first-quarter net profit rose to ₹40.01 crore from ₹22.32 crore, while revenue increased to ₹492.97 crore from ₹424.68 crore. Kalpataru Projects International reported net profit of ₹310 crore against ₹214 crore previously. Siemens’ reported profit included a ₹2,099 crore gain from the sale of discontinued operations, while its EBITDA declined and margin narrowed, making the headline profit increase less reflective of underlying operating performance.

Corporate announcements included ₹541 crore of additional orders for Bharat Electronics since July 31, a 1,166 MW renewable-capacity addition by JSW Energy since April 2026, and a ₹513.93 crore battery-storage and BSNL-tower order for Bondada Engineering’s arm. Lupin received US FDA approval for a generic version of Lokelma, while L&T Technology Services launched an agentic-AI platform for engineering and manufacturing companies.

BSE is scheduled to replace Wipro in the Nifty 50 from September 30, 2026. Nuvama estimated potential passive inflows of $695 million into BSE shares, although the session’s market reaction was not solely attributable to that index change.

The primary market remained active. Dhoot Transmission’s ₹3,067 crore IPO was fully subscribed on its second day of bidding, with the issue scheduled to close on August 12. Its price band was ₹829–871 a share, and listing was expected on August 17.

Milky Mist Dairy Food opened its ₹1,553 crore IPO on August 11 and is scheduled to close on August 13. The issue includes a ₹1,428 crore fresh issue and a ₹125 crore offer for sale. Leap India and Technocraft Ventures were scheduled to close their offerings on August 11.

A reported block-style investment in Anawil Wire & Engineering involved purchases by Abakkus Venture Opportunities Fund, Carnelian AIF, Motilal Oswal Financial Services and Frangipani Capital Advisors. The available material did not identify a separate exchange-reported block-deal price or counterparty transaction beyond those purchases.